Topical verapamil HCl, topical trifluoperazine, and topical magnesium sulfate for the treatment of Peyronie's Disease - A Placebo-Controlled Pilot Study

Journal of Sexual Medicine

Volumn 4, Issue 2, 2007, Pages 477-484

  Fitch, William P ^a   Easterling, W Jerry ^b   Talbert, Robert L ^c   Bordovsky, Michael J ^a   Mosier, Michael ^d  

^a PDL ^*

^b PDL   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d WASHBURN UNIVERSITY   (United States)

Author keywords

Calcium Channel Blocker; Peyronie's Disease; Placebo; Topical Verapamil

Indexed keywords

MAGNESIUM SULFATE; PLACEBO; TRIFLUOPERAZINE; VERAPAMIL;

ADULT; AGED; AGITATION; ANALGESIA; ANXIETY; ARTICLE; BLURRED VISION; CLINICAL TRIAL; CONTACT DERMATITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PENIS ERECTION; PEYRONIE DISEASE; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 33947174768     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2006.00417.x     Document Type: Article

References (11)

1. Peyronie F. de la: Sur quelques obstacles qui s'opposerta l'ejaculation naturelle de la semence. Mem'l Acad. Roy de Chir 1743; I: 425-34.
2. Lindsay MB, Schain DM, Grambsch P, Benson RC, Beard CM, Kurland LT. The incidence of Peyronie's Disease in Rochester, Minnesota, 1950 through 1984. J Urol 1991; 146: 1007-9.
3. Schwarzer U, Klotz T, Braun M, Wassmer G, Englemann U. Prevalence or Peyronie's Disease: Results of an 8,000 man survey. J Urol Suppl 2000; 163: 167, abstract 742.
4. Rhoden EL, Teloken C, Ting HY, Lucas ML, Teodosio da Ros C, Ary Vargas Souto C. Prevalence of Peyronie's Disease in men over 50-y-old from Southern Brazil. Int J Impot Res 2001; 13: 291-3.
5. Aggeler J, Frisch SM, Werb Z. Changes in cell shape correlate with collagenase gene expression in rabbit synovial fibroblasts. J Cell Biol 1984; 98: 1662-76.
6. Kelly RB. Pathways of protein secretion in Eukaryotes. Science 1985; 230: 25-32.
7. Laurence A, Levine Karen E, Goldman Jason M. Greenfield: Experience with intraplaque injection of verapamil for Peyronie's Disease. J Urol 2002; 168: 621-6.
8. Lee RC, Ping JA. Calcium antagoniss retard extracellular matrix production in connective tissue equivalent. J Surg Res 1990; 49: 463-6.
9. Martin DJ, Badwan K, Parker M, Mulhall JP. Transdermal application of verapamil gel to the penile shaft fails to infiltrate the tunica albuginea. J Urol 2002; 168: 2483-5.
10. Saseen JJ, Porter JA, Barnette DJ, Zajec EJ Jr, Carter BL. Postabsorption concentration peaks with brand-name and generic verapamil: A double blind, cross-over study in elderly hypertensive patients. J Clin Pharmacol 1997; 37: 526-34.
11. Alberts B, Bray D, Lewis J, Raff M, Roberts K, Watson J. Molecular biology of the cell, 3rd edition, CH 19. Garland Publishing Inc: New York, NY; 1994: 978-95.